Neurocrine Biosciences
NBIX
#1452
Rank
NZ$26.36 B
Marketcap
NZ$259.39
Share price
-0.19%
Change (1 day)
7.96%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): NZ$12.24

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$12.52. In 2025 the company made an earnings per share (EPS) of NZ$8.56 an increase over its 2024 EPS that were of NZ$6.00.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$12.2443.05%
2025NZ$8.5642.6%
2024NZ$6.0033.07%
2023NZ$4.5157.76%
2022NZ$2.8669.47%
2021NZ$1.69-78.21%
2020NZ$7.74990%
2019NZ$0.7181.82%
2018NZ$0.39-113.5%
2017NZ-$2.890.62%
2016NZ-$2.8857.28%
2015NZ-$1.8325.61%
2014NZ-$1.4618.84%
2013NZ-$1.23-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$1.35-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$6.34-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$53.06 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$1.33-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.60-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$8.58-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$13.40-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.33-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK